The Latest Breaking News from FDA

You can't patent naturally-occurring molecules like psilocybin. That's led to a rush to find a synthetic blend

Emergent BioSolutions has applied to the Food and Drug Administration to sell the opioid overdose-reversal drug over the counter. Addiction experts say it may be a key step to lower fentanyl deaths.

Aspartame, an artificial sweetener included in approximately 5,000 diet goods and beverages, has been linked by Florida State University College of Medicine researchers to anxiety-like behaviour in mice. Read on for details:

A new generation of FDA-approved diabetes drugs that can also help patients lose weight has prompted enthusiasm from doctors and a firestorm of demand among patients so strong it's led to shortages.

Studies show the products may double the risk of uterine cancer, but tradition, societal pressure and personal taste create obstacles to change

Nearly 6 million Americans have taken Paxlovid for free, courtesy of the federal government. The Pfizer pill has helped prevent many people infected with COVID-19 from being hospitalized or dying, and it may even reduce the risk of developing long COVID. But the government plans to stop footing the bill…

FORT LAUDERDALE, Fla. — Harni Patel, pharmacist and owner of Tamarac Pharmacy, finds herself fielding calls daily from panicked parents of feverish children searching for everything from Children’s Tylenol to Amoxicillin to Tamiflu.

Amid the stock market chaos due to the Fed’s fight against inflation and recessionary concerns, dividend stocks are gaining traction. Fundamentally strong dividend stocks can provide protection and ensure stable income. So, high-yield dividend stocks Pfizer (PFE), BHP Group (BHP), and Caledonia Mining (CMCL), with significant upside potential, might be…

Wall Street looks bullish on Biogen’s (BIIB) prospects after the company’s success during the Phase 3 clinical trial of lecanemab. The drug could boost the company’s financials significantly as it could herald a new era for people with Alzheimer’s disease. Its bright growth prospects have earned it a Strong Buy…